FOXM1-IN-3

FOXM1-IN-3 (compound 14) (6.25-100 μM; 24 h) potently inhibits proliferation in SW620 and SW480 colorectal cancer cells with IC₅₀ values of 14.9 μM and 17.5 μM, respectively, and shows favorable selectivity over normal CCD841 cells (IC₅₀ of 36.65 μM)^[1].
FOXM1-IN-3 (0.75-3 μM; 7 days) almost completely inhibits colony formation in SW480 and SW620 cells at 3 μM, reflecting long-term antiproliferative effects^[1].
FOXM1-IN-3 (6.25-25 μM; 48 h) suppresses cell migration in SW480 cells at 6.25 μM and in SW620 cells at 12.5 μM over 48 h^[1].
FOXM1-IN-3 shows measurable inhibition of PI3Kβ, γ, and δ^[1].
FOXM1-IN-3 (6.25-25 μM; 24 h) downregulates FOXM1 and its downstream effectors CCNB1 and CDC25 in SW480 and SW620 cells at concentrations as low as 6.25 μM^[1].
FOXM1-IN-3 (6.25-25 μM; 24 h) causes G₂/M phase arrest in SW480 and SW620 cells, correlating with FOXM1 downregulation^[1].
FOXM1-IN-3 (6.25-25 μM; 24 h) induces apoptosis in SW480 and SW620 cells at 12.5 μM and 25 μM^[1].
FOXM1-IN-3 (10 μM; 24 h, 48 h) selectively targets cancer stem cell (CSC) phenotypes in SW480 and SW620 cells at 10 μM, with mild and reversible effects on normal CCD841 cells^[1].
FOXM1-IN-3 has high passive permeability, low CYP interference, notable hepatotoxicity (IC₅₀ ~5.6 μM in HepG2), and lower neurotoxicity (IC₅₀ ~17 μM in SH-SY5Y)^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.